InvestmentJun 22, 2026, 08:51 AM
InterCure Secures NIS 22M Funding, Potentially NIS 54M
AI Summary
InterCure Ltd. announced binding term sheets for funding commitments totaling NIS 22 million (approximately US$7.4 million) through a private placement. This amount could increase to NIS 54 million (approximately US$18.6 million) if warrants are fully exercised. The funding, which includes investments from CEO Alexander Rabinovich and Bennu Pharma Fund Ltd., will be used to support the company's global expansion, meet growing demand in Germany and regulated U.S. medical cannabis markets, and aid in the recovery and expansion of its Nir Oz facility.
Key Highlights
- InterCure secured NIS 22 million (US$7.4 million) in funding commitments via private placement.
- Funding may increase to NIS 54 million (US$18.6 million) if warrants are fully exercised.
- Company to issue 7,895,143 ordinary shares at NIS 2.75 (US$0.94) per share.
- Warrants issued for up to 7,895,143 ordinary shares at NIS 4.125 (US$1.41) per share.
- Key investors include CEO Alexander Rabinovich and Bennu Pharma Fund Ltd.
- Proceeds will support global expansion, including Germany and US medical cannabis markets.
- Funding also aids recovery and expansion of the Nir Oz facility.
Price Impact
More from INCR